IST5-002，一种有效的STAT5a/b抑制剂，选择性地抑制 STAT5a/b 的转录活性，IC50值分别为 1.5 μM (STAT5a) 和 3.5 μM (STAT5b)。 IST5-002 诱导前列腺癌细胞和慢性粒细胞白血病 (CML) 细胞凋亡 (apoptotic) 和死亡。IST5-002 可用于前列腺癌和慢性粒细胞白血病 (CML) 的研究。

IST5-002, a potent Stat5a/b inhibitor, selectively inhibits transcriptional activity of Stat5a/b ( IC 50 s: 1.5 μM for Stat5a, 3.5 μM for Stat5b). IST5-002 inducs cell apoptotic and death of prostate cancer cells and chronic myeloid leukemia (CML) cells. IST5-002 can be used in the research of prostate cancer and chronic myeloid leukemia (CML) [1].

IST5-002 (1.5-25 μM, 2 h) inhibits transcriptional activity of Stat5a and Stat5b in a dose-dependent manner [1]. IST5-002 (0-40 μM, 3 h) inhibits Bcr-Abl-induced Stat5a/b phosphorylation in K562 cells [1]. IST5-002 (5-100 μM, 2 h) inhibits Stat5a/b phosphorylation in T47D cells, and inhibits dimerization in PC-3 cells [1]. IST5-002 (5-100 μM, 2 h) suppresses Stat5 nuclear translocation in PC-3 cells, and inhibits DNA binding of Stat5 target genes and COS-7 cells [1]. IST5-002 (2-50 μM, 48 h) reduces expression of Stat5a/b target genes (Bcl-xL and cyclin D1) in CWR22Rv1 and LNCaP cells [1]. IST5-002 (3.1-50 μM, 72 h) inhibits cell growth through induction of apoptosis in human prostate cancer cells [1]. IST5-002 (25-100 μM, 7 days) induces epithelial cell death in patient-derived prostate cancers ex vivo in organ explant cultures [1]. IST5-002 (5 μM, 24-72h) inhibits Stat5a/b phosphorylation and induces apoptosis of Imatinib -sensitive and -resistant CML cells [1]. Cell Viability Assay [1] Cell Line: CWR22Rv1, LNCaP, and DU145 cells Concentration: 3.1, 6.3, 12.5, 25, 50 μM Incubation Time: 72 h Result: Decreased viable cells by 50% to 80% at 12.5 μM. Cell Cycle Analysis [1] Cell Line: LNCaP and CWR22Rv1 cells Concentration: 6, 12, 25 μM Incubation Time: 72 h Result: Increased the fraction of dead cells (sub-G1) and decreased the fraction of living cells (G2–M). Western Blot Analysis [1] Cell Line: Bcr-Abl–positive K562 cells Concentration: 0, 1, 5, 10, 20, 40 μM Incubation Time: 3 h Result: Inhibited Bcr-Abl-induced Stat5a/b phosphorylation at 5 μM, without affecting Bcr-Abl tyrosine phosphorylation levels. Immunofluorescence [1] Cell Line: PC-3 cells Concentration: 5, 10, 15. 20, 40 μM Incubation Time: 2 h Result: Inhibited Prl (Prolactin)-induced nuclear translocation of Stat5.

RORγt inverse agonist 29 (intraperitoneal injection, 25-100 mg/kg, daily for 10 days) inhibits tumor growth in prostate cancer xenograft model [1]. Animal Model: Prostate cancer (CWR22Rv1) xenograft model [1] Dosage: 25, 50, and 100 mg/kg Administration: Intraperitoneal injection, daily for 10 days Result: Induced massive loss of viable tumor cells and dead rounded cells accumulation. Induced cell death through apoptosis (shown by fragmented DNA in tumor sections). Decreased nuclear Stat5a/b content by 60%, 78%, and 90% at 25, 50, and 100 mg/kg, respectively.

13484-66-7

C17H20N5O7P

437.34

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years